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Abstract: Anticholinergics are frequently prescribed for older adults and can lead to adverse drug events. The novel MARANTE
(Muscarinic Acetylcholinergic Receptor ANTagonist Exposure) scale measures the anticholinergic exposure by incorporating
potency and dosages of each medication into its calculations. The aims were to assess prevalence and intensity of the anticholin-
ergic exposure in a longitudinal cohort study of community-dwelling patients aged 80 years and over (n = 503) and to study the
impact on mortality and hospitalization. Chronic medication use at baseline (November 2008–September 2009) was entered and
codified with the Anatomical Therapeutic Chemical classification. Time-to-event analysis until first hospitalization or death was
performed at 18 months after inclusion, using Kaplan–Meier curves. Cox regression was performed to control for covariates.
Mean age was 84 years (range 80–102), and mean number of medications was 5 (range 0–16). Prevalence of anticholinergic use
was 31.8%, with 9% taking ≥2 anticholinergics (range 0–4). Main indications for anticholinergics were depression, pain and
gastric dysfunction. Female gender, the level of multi-morbidity and the number of medications were associated with anticholin-
ergic use. Mortality and hospitalization rate were 8.9% and 31.0%, respectively. After adjustment for the level of multi-morbidity
and medication intake, multi-variable analysis showed increased risks of mortality (HR 2.3, 95% CI: 1.07–4.78) and hospitaliza-
tion (HR 1.7; 95% CI: 1.13–2.59) in those with high anticholinergic exposure. The longitudinal study among Belgian commu-
nity-dwelling oldest old demonstrated great anticholinergic exposure, which was associated with increased risk of mortality and
hospitalization after 18 months.
Medications with anticholinergic properties (anticholinergics)
block the effect of acetylcholine on the muscarinic and
nicotinergic receptors in central or peripheral organ systems,
inhibiting the acetylcholine-mediated response [1–5]. Anti-
cholinergics are widely prescribed in older patients [4–6] for
several indications (including depression, psychosis, allergy).
Often prescribers do not perceive the prescribed drug as an
anticholinergic [7].
On top of the higher level of comorbidities and the higher
overall medication intake, older persons become more sensi-
tive to the side effects of anticholinergics due to a decreased
elimination of medications, as well as an increased permeabil-
ity of the blood–brain barrier [6,8–10]. Inhibition of acetyl-
cholinergic mediated muscle contraction can lead to peripheral
side effects, which include blurred vision, urine retention or
constipation. Competitive binding to muscarinic brain recep-
tors can lead to central nervous symptoms, which include
dizziness, hallucinations or confusion. These side effects can
again in the long-term lead to the appearance of delirium [11],
impaired cognitive function[12], an increased number of falls
[13] and hospital readmission risk [14]. Usage of anticholiner-
gics has been linked to an increased risk of mortality and hos-
pitalization [15,16].
Only scoring the anticholinergic potency of medications to
quantify the anticholinergic exposure is deemed too simplistic
as it should also incorporate the dose relationship [17]. In the
past decades, several anticholinergic risk scales (ARS) have
been created to measure the anticholinergic burden in older
patients. All these tools list medications with anticholinergic
properties and quantify the intrinsic burden of each medication
[18–24], but there is a significant variation on included drugs
[25]. Dosage is only taken into account in two of them. The
ARS by Carnahan et al. [18] uses the maximal effective
dosage, and it does not take dosage adjustments for older per-
sons into account. The Drug Burden Index (DBI) calculates
the anticholinergic burden using only the minimal effective
value of medications. However, the anticholinergic nature of
the medications listed in the DBI is unclear[52]; the DBI does
not incorporate the anticholinergic potency of medications,
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and finally, the minimal effective value of medications was
determined for a younger population.
Results from studies using one dosage reference point did
not validate whether a higher anticholinergic exposure is
related to mortality or hospitalization, neither in the short nor
the long-term [13,26–28]. Therefore, this study aimed (i) to
determine accurately the point-prevalence and the intensity of
the anticholinergic exposure using the Muscarinic Acetyl-
cholinergic Receptor ANTagonist Exposure through the MAR-
ANTE scale in a prospective cohort of oldest old primary care
patients (aged 80 years and over) and (ii) to investigate associ-
ations with mortality and first hospitalization during an obser-
vation period of 18 months.
Methods
Sample. We used the Belfrail-Med cohort [29,30] of 503 Belgian
community-dwelling primary care patients aged 80 years and over. All
subjects were recruited by their own general practitioner between
November 2008 and September 2009. Exclusion criteria were known
dementia and being treated in palliative care.
Data collection. Baseline data included personal, clinical, functional
and medication data and were collected by trained investigators and
general practitioners (GPs). The trained investigators conducted
structured questionnaires and standardized tests to collect personal
(age, gender, life situation) and functional data (physical activity,
activities of daily living and cognitive impairment). GPs performed
clinical examinations and used their medical records to collect
medication information and clinical data (current and past clinical
problems to assess the level of multi-morbidity). For a full
background on the data collection and construction of the level of
multi-morbidity (Cumulative Illness Rating Scale, CIRS), see previous
publications [29,31].
The GPs recorded all chronic medications at baseline. Chronic medica-
tions were defined as entries on the medication list without a stop date.
All chronic medications with systemic effect were codified into the
Anatomical Therapeutic Chemical classification (WHO ATC/DDD 2013)
[32] based on the official register of medications on the Belgian market.1
Clinical and functional data handling. For a full background on the
clinical and functional data handling, we refer to the original Belfrail-
Med article [29,30].
To measure the level of multi-morbidity, the Cumulative Illness
Rating Scale (CIRS) was used [32]. The CIRS measures the chronic
medical illness burden while taking into consideration the severity of
chronic diseases [33]. For the construction of the CIRS, all current
and past medical problems were used. Of 14 body systems, every
body system affected with severe disease was counted, to a possible
range of 14 [31,33].
To measure the physical activity, the LASA Physical Activity Ques-
tionnaire (LAPAQ) was used [34]. For our calculations, we divided
the raw LAPAQ scores (range 0–∞) into quartiles to identify the low-
est scoring quartile as those with the lowest physical activity.
Activities of daily living (ADL) were derived from the KATZ scale,
which measures the care dependency in six domains: bathing, cloth-
ing, toileting, transferring, continence and feeding [35]. For our calcu-
lations, we divided the raw KATZ ADL scores (range 6–30) to
identify those most care dependent (scoring 13 and more).
To identify cognitive impairment, we relied on the Mini-Mental
State Examination (MMSE) [36]. A cut-off adapted to the age and
level of education of the respondents was used to identify cognitive
impairment [37].
Assessing anticholinergic exposure. To evaluate anticholinergic
exposure, we used the MARANTE scale, based on the systematic review
by Duran et al. [38] and a methodological study by Klamer & Wauters
[39]. Duran listed 100 active substances with anticholinergic properties
originating from seven anticholinergic risk scales (ARSs) and categorized
them according to their anticholinergic potency (low or high) [38]. In
Klamer & Wauters’ study, for [39] active substances (increasing to 69
when counting variations of routes of administration, pharmaceutical
forms, or combination products), three dosage reference values were
identified. All reference values were based on information from
authoritative sources and then validated and completed by an expert panel.
Calculating the anticholinergic exposure. The MARANTE scale is
the summation of all anticholinergic loads in a patient’s medication
list. The anticholinergic load is calculated by multiplying the values of
potency and daily dosage of each medication. Patients not taking
anticholinergics receive a score of 0. A complete overview of the
calculation of the score on the MARANTE scale is given in Box 1.
For potency, we used the distinction between a low and high anti-
cholinergic potency as suggested in Duran’s list and the Klamer and
Wauters study [39], with a value of 1 for low potency, and 2 for high
potency anticholinergics.
For dosage, we determined the daily dosage per anticholinergic
from the posology instructions in the medication list. The daily dosage
equals the sum quantities of all doses given to a patient of a specific
medication during the course of 1 day.
This daily dosage is compared to the reference values (set in Kla-
mer et al. [39]), and based on the pharmacological concepts: minimal
geriatric effective value (GMinEV), maintenance geriatric dosage
(GMainD) and maximum geriatric effective value (GMaxEV). These
reference points permit to accord values for very low, low, high and
very high daily dosage ranges.
• A dosage higher than 0 mg and below GMinEV received a
dosage score of 0.5.
• A dosage equal/higher than GMinEV and below the mainte-
nance geriatric dosage (GMainD) was scored 1.
• Equal/above GMainD and below the maximal effective geriatric
dosing (GMaxEV) was scored 1.5,
• All dosages equal/above GMaxEV received a dosage score 2.
Follow-up data. Follow-up data included data on mortality (date and
cause of death) and hospitalization (date of the first hospitalization)
during an observation period of 18 months. A hospitalization was
defined as an unplanned hospital stay lasting longer than 1 day. Index
date was the date of baseline assessment.
Statistical analysis. All statistical analyses were carried out using
SPSS 21.0 (Statistical Package for Social Sciences, SPSS Inc.,
Chicago, IL, USA). For all variables, there was less than 5% missing
data [29].
Descriptive statistics include means and standard deviations or range
for normally distributed data, and medians with interquartile range for
skewed data. Categorical data were expressed using numbers and
percentages.
After calculation of all the scores of the MARANTE scale, the
results were categorized in low and high anticholinergic exposure,
based on the median of the distribution (lower than and above the
median). For each patient, we also calculated separately the sum of
the values for potency, and the sum of values for the dosage, to
explore the impact of the two elements of the MARANTE scale.
1Source: https://www.ehealth.fgov.be
© 2016 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
592 MAARTEN WAUTERS ET AL.
Time-to-event analysis was estimated using the Kaplan–Meier
method, with the log-rank test verifying differences in time-to-event
between groups (no versus low, low versus high and no versus high
anticholinergic exposure). A follow-up period of 18 months after
inclusion was used to observe direct associations of mortality and
unplanned hospitalization with the baseline anticholinergic exposure of
patients. Death or unplanned first hospitalization was considered as
events. For hospitalization, additional censoring was applied for
patients who died. All relations between anticholinergic exposure and
outcome were based on the baseline medication intake without proof
of a continuous (chronic) anticholinergic intake throughout the study
period.
Univariable and multi-variable analyses were carried out to calculate
Hazard Ratios for the associations with mortality and hospitalization.
The MARANTE scale was used in univariable and multi-variable
analyses as a continuous variable but also as categorical variable. Cat-
egories dividing no, low and high exposure were formed based on the
distribution of the scores on the MARANTE scale. Categorical analy-
sis was performed to observe trends in associations between anti-
cholinergic exposure and outcome. In the multi-variable analysis, we
corrected the associations with outcome, for the number of medica-
tions taken at baseline and with the level of multi-morbidity. The level
of multi-morbidity (CIRS, as a continuous variable) was chosen
because of the dominating association over other patient characteristics
(for more background details, see the original Belfrail-Med paper
[40]).
Ethical approval. The study protocol was approved by the
Biomedical Ethics Committee of the Medical School of the Universite
catholique de Louvain (UCL), Brussels (B40320084685 on 27/10/
2008) and later by the Ethics committee of Ghent University Hospital
(B670201421408 on 26/06/2014). All participants provided informed
consent.
Results
Description of the population.
The mean age of patients in the Belfrail-Med cohort
(n = 503) was 84.4 years (range 80–102). The majority was
female (61%) and with a low level of education (≤8 years,
69%).
The median level of multi-morbidity, expressed by the
CIRS, was 4 (range 1–9). The most common clinical problems
were hypertension (70.4%), osteoarthritis (57.1%), hyperlipi-
daemia (44.1%) and heart failure (38.4%).
The mean number of chronic medications prescribed was
5.4 (range 0–16). Prescribing of 5 or more medications was
present in 57.7%, and in 0.8%, there was no chronic medica-
tion use. Predominant main anatomical medication classes (1st
ATC level) were cardiovascular medications (in 86.3% of the
population), followed by blood regulating medications
(56.1%), and nervous system medications (54.5%). The most
prescribed therapeutic subgroup (2nd ATC level) was
antithrombotic medications (54.5%).
All personal and clinical characteristics, as well as the descrip-
tion of the general medication use of the study population, are
given in table 1.
Description of the anticholinergic use.
In this population of community-dwelling oldest old, 68.2%
had no medications with anticholinergic properties prescribed
on a chronic basis; 23% were taking 1 anticholinergic; 7.0%
2, 1.2% 3 and 0.6% were taking four anticholinergics.
In total, 217 prescriptions of medication with anticholinergic
properties were identified. Most often these anticholinergic
prescriptions were of low potency (80.0%). The dosages in
which anticholinergics were prescribed were rarely considered
too low (1.8% below GMinEV), yet often high (51.5% above
GMainD) or very high (17.1%, above GMaxEV).
Medications with anticholinergic effects (n = 217) were pre-
dominantly ATC N (nervous system medications) for the treat-
ment of depression (35.0%, predominantly escitalopram,
trazodone and citalopram) or for pain (18.4%, predominantly
tramadol). Other predominantly prescribed medications in
ATC A (alimentary medications) were for the treatment of
gastrointestinal disorders/peptic ulcers (20.7%; predominantly
ranitidine and domperidon). Anticholinergics in ATC R
(respiratory agents) were for treatment of asthma (8.8%) or
Table 1.
Personal, clinical and functional characteristics and the general
medication use of the study population (n = 503).
%
Personal
Mean age in years (range) 84.4 (80–102)
Gender (% female) 61.2
Low education (≤8 years) 69.2
Living alone 43.3
Clinical1
Median level of Multi-morbidity (range) 4 (IQR 3–5)
Hypertension 70.4
Osteoarthritis 57.1
Hyperlipidaemia 44.1
Heart Failure (NYHA2 > 0) 38.4
Obesity (BMI > 30 kg/m²) 27.9
Osteoporosis 20.9
Functional Median (IQR)
Activities of daily living, ADL 6 (6–8)
Physical activity, LAPAQ 70 (30–102)
Mental status, MMSE 28 (26–29)
Medication use
Mean number of chronic medications 5.4 (range 0–16)
Patients with polypharmacy
(5 or more)
57.7
Most prevalent prescribed medication subclasses (>15%)
Antithrombotic agents 54.5
Beta blocking agents 41.9
Medications acting on RAAS 41.9
Benzodiazepines and Z-drugs 35.6
Lipid modifying medications 33.2
Diuretics 32.0
Drugs for acid related disorders 24.5
Calcium channel blockers 24.3
Cardiac therapy medications 20.7
Mineral supplements 16.7
Analgesics 16.5
Antidepressants 16.1
Medications used in diabetes 15.9
IQR, Interquartile range.
1Clinical problems with prevalence above 20% are listed.
2New York Heart Association (NYHA) functional classification of
heart failure.
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ATC G (genito-urinary medications) for the treatment of uri-
nary problems (5.5%).
Description of the anticholinergic exposure.
The scores on the MARANTE Scale ranged between 0 and 7.
Based on the distribution of the MARANTE, two equal
groups were created. One low-exposure group (MARANTE
0.5–1.5, 16.1%) and a high-exposure group (MARANTE ≥ 2,
15.7%). As a consequence, to be categorized into the high-expo-
sure group, it would sufficient to take one high potency anti-
cholinergic at a low dose (above GMinEV) or a low potency at
a very high dose (above GMaxEV). To be categorized into the
low-exposure group, a high potency could only be taken at the
lowest dose (below GMinEV) or a low potency at a dose lower
than the GMaxEV, or the combinations of maximum three low
potency anticholinergics at the lowest doses.
The description of the anticholinergic use is given in
table 2.
Patient characteristics associated with anticholinergic use.
All personal, clinical, functional and medication characteristics
associated with the use of anticholinergics are presented in
table 3.
Personal factors associated with anticholinergic use were
female gender (OR 1.55, 95% CI 1.04–2.30) and low educa-
tion (OR 1.80, 95% CI 1.16–2.79). Age was not associated
with anticholinergic use in this cohort of oldest old patients.
Clinical characteristics associated with anticholinergic use
included the level of multi-morbidity (OR 1.28, 95% CI 1.14–
1.44), predominantly depression (OR 5.22, 95%CI 2.99–9.12).
For the functional characteristics, physical inactivity (OR 2.05,
95% CI 1.34–3.12), but neither cognitive impairment nor care
dependency showed associations with anticholinergic use.
Both the level of medication use (expressed as a continuous
variable) and the dichotomous variable of polypharmacy were
strongly associated with anticholinergic use.
Survival analysis of anticholinergic exposure on mortality and
hospitalization.
The unadjusted survival analyses of different categories of
anticholinergic exposure on mortality and first hospitalization
are given in Graph 1.
The mortality rate after 18 months was 8.9% (n = 45).
Most common causes of death were cardiovascular and/or
cerebrovascular related events (48.9% of deaths), cancer
(20.0%), respiratory-related events (13.3%) or general deterio-
ration (6.7%). The survival rate was lower among those who
had high anticholinergic exposure, as compared to those with-
out. There was only a significant difference in survival per-
centage between those with no (93.3%) versus those with high
(85.0%, p = 0.001) anticholinergic exposure.
The time-to-event analysis showed that the probabilities of
having a hospitalization (31%, n = 156) varied among the cat-
egories of anticholinergic exposures. Those with high anti-
cholinergic potency (45.7%) had a significantly lower
hospitalization rate than those with no (74.6%, p < 0.001) and
low anticholinergic exposure (68.2%, p = 0.003). There was
no difference in survival rates (p = 0.626) in those with low
and no anticholinergic exposure.
Univariable analysis for the association of the MARANTE
scale with mortality and hospitalization.
All univariable associations with mortality and first hospital-
ization are given in table 4.
For mortality and for hospitalization, the continuous vari-
ables for the number of anticholinergics, the potency score, the
dosage score and the score on the MARANTE Sale, showed all
significant increased risks. The hazard ratio for the MARANTE
scale had a more narrow confidence interval than the potency
and dosage scores for outcome of both, potentially indicating a
higher precision. For the low anticholinergic exposure category,
no significantly increased risks were observed.
Age, the level of multi-morbidity (CIRS) and the number of
medications were also associated with mortality and
hospitalization.
Those with a high anticholinergic exposure (MARANTE
scale ≥2) had a 2.8-times increased risk of mortality (HR 2.77,
95% CI 1.43–5.38) and a 2.4-times increased risk of hospital-
ization (HR 2.36, 95% CI 1.63–3.42) compared to those with
no anticholinergic exposure.
Multi-variable associations with mortality and first hospitaliza-
tion are given in table 5. Two models are presented–the first was
Table 2.
Description of anticholinergic use in the study population (n=503)
General description n = 503 %
Anticholinergics use 31.8%
Range of number of Anticholinergics 0–4
Range of potency scores 0–5
Range of dosage scores 0–6
Range of scores on the MARANTE scale 0–7
Details of anticholinergics n = 217 %
Potency Low 80.0
High 20.0
Dosage Below GMinEV (very low) 1.8
Above GMinEV (low) 30.0
Above GMainD (high) 51.5
Above GMaxEV (very high) 17.1
Most prevalent anticholinergics (>2%) n = 217
A02BA02 Ranitidin 14.7
N02AX02 Tramadol 10.1
N06AB10 Escitalopram 8.8
R03AL01 Ipratropium bromide* (+ Fenoterol) 7.4
N06AX05 Trazodone 7.4
A03AF03 Domperidone 5.5
N02AX52 Tramadol (combination products) 5.5
N06AB04 Citalopram 4.6
G04BD04 Oxybutinin* 4.1
N06AA09 Amitriptyline* 3.7
N06AX11 Mirtazapine 3.7
N06AB05 Paroxetine 3.7
Anticholinergic Exposure (MARANTE) categories n = 503 %
No 0 68.2
Low 0.5–1.5 16.1
High ≥2 15.7
Medications market with an * are high potency anticholinergics.
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adjusted for the number of medications and the second for both
the number of medications and for the level of multi-morbidity.
Associations between the number of anticholinergics, the
potency score and dosage score disappeared in the multi-
variable analysis.
The analysis based on the scores on the MARANTE scale
did yield statistically significant and clinically relevant results.
For outcome of both, the Hazard Ratio for the MARANTE
scale (continuous variable) had more narrow confidence inter-
vals than the potency and dosage scores, potentially indicating
higher precision.
In the multi-variable analysis model, the anticholinergic
exposure quantified by the MARANTE scale was categorized
and adjusted for confounding variables. Only significant asso-
ciations were found for those with high anticholinergic expo-
sure for both mortality (HR 2.20, 95% CI 1.03–4.67) and for
first unplanned hospitalization (HR 1.71, 95% CI 1.13–2.59).
Discussion
Main findings.
In this longitudinal study, we applied for the first time a new
anticholinergic scale based on both potency and the whole
dosage spectrum. Our main finding is that the MARANTE
scale is a robust and potent approximation for quantifying
anticholinergic exposure.
We were able to show that a third of this community-dwell-
ing cohort over oldest old (aged 80 years and older) takes
chronically at least one medication with anticholinergic prop-
erties. Anticholinergics with low potency (80% of all anti-
cholinergics) were most consumed, yet dosing was considered
often high (52%) or very high (17%) in this population.
Based on the median score on the MARANTE scale in sub-
set of patients with anticholinergic exposure, equal groups
were created. Those with a high anticholinergic exposure (a
score ≥2 on the MARANTE scale) showed increased risks of
both mortality and hospitalization in multi-variable analysis,
controlling for the number of medications and the level of
multi-morbidity. These patients showed a 2.2-times increased
risk of mortality, and a 71% increased risk of being hospital-
ized during an observation period of 18 months.
Strengths and limitations.
We explored the point-prevalence and intensity of the
anticholinergic exposure at baseline in a cohort of community-
dwelling oldest old with a new measurement instrument,
Table 3.
Univariable analysis of personal, clinical, functional characteristics and medication use of the Belfrail-Med cohort (n = 503) in relation to
anticholinergic use.
Anticholinergic use? (%)
p-value Univariable odds ratio (95% CI)
Yes No
n = 160 n = 343
Personal
Mean age (in years) 84.5 84.4 0.718
Female gender 68.1 58.0 0.030 1.55 (1.04–2.30)
Living alone 44.4 42.9 0.749
Low education (≤8 years) 78.0 66.3 0.008 1.80 (1.16–2.79)
Clinical
Mean comorbidity, CIRS 4.2 3.6 <0.001 1.28 (1.14–1.44)
Hypertension 65.0 73.1 0.064
Osteoarthritis 69.6 52.8 <0.001 2.05 (1.37–3.06)
Hyperlipidaemia 46.8 44.6 0.639
Heart Failure 40.6 37.3 0.477
Osteoporosis 32.4 18.9 0.001 2.39 (1.52–3.75)
Obesity 30.4 27.8 0.548
Diabetes 18.9 19.1 0.959
Post-myocardial infarction, post-stroke 20.6 17.9 0.472
COPD/Asthma 19.4 12.5 0.045 1.68 (1.01–2.83)
Depression 26.6 6.5 <0.001 5.22 (2.99–9.12)
Chronic renal failure 16.8 8.9 0.011 2.06 (1.17–3.61
Functional
Most care dependent (ADL)1 6.3 10.7 0.120
Most physical inactive (LAPAQ)2 34.8 20.6 0.001 2.05 (1.34–3.12)
Cognitive impairment (MMSE)3 15.9 14.9 0.774
Medication related
Mean Number of medications (0–16) 7.2 4.6 <0.001 1.39 (1.29–1.51)
Polypharmacy users 78.8 47.8 <0.001 4.05 (2.62–4.24)
Only significant univariable odds ratios are shown.
1Highest care dependency was defined as respondents scoring ≥13 (9.1%) on the KATZ ADL scale.
2Lowest physical active was defined as the quartile (25.2%) with the lowest raw score on the LAPAQ.
3Cognitive impairment was defined using the MMSE, adjusted for age and level of education.
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taking into account potency and dosage. We studied the inten-
sity of the baseline anticholinergic exposure, by looking at
associations with mortality and first unplanned hospitalization
using a prospective cohort during an observation period of
18 months, The observational nature of this study does not
permit to ascertain causal relations of the anticholinergic expo-
sure with outcome. Confounding by indication is possible as
anticholinergics are used in patients with multiple diseases, all
possibly associated with the outcome.
In multi-variable analysis, taking into account multi-morbid-
ity and polypharmacy, simple measures of anticholinergic
exposure (number of anticholinergics, sum of values for
potency, sum of values for dosage) failed to observe signifi-
cant results. Only the application of the MARANTE Scale,
and the subsequent categorization in two groups of low and
high exposure revealed that high anticholinergic exposure is
associated with mortality and hospitalization.
Only the chronic medication use was analysed (no if-needed
or over-the-counter medications), potentially underestimating
the anticholinergic exposure. All associations with mortality or
first hospitalization were based on the baseline chronic medi-
cation intake, without control for a continuous chronic anti-
cholinergic intake during the observation period.
It should also be remembered that this cohort was limited to
community-dwelling active and cognitively fit oldest old,
limiting the transferability and interpretation into other
populations.
In this study, only associations with mortality and hospi-
talization were analysed. The data collection of the original
Belfrail cohort was not intended to look at the symptomatic
adverse events of medications (e.g. sedation). All partici-
pants were randomly and consecutively selected by their
GPs; thus, some degree of prevalent user bias cannot be
excluded.
The MARANTE scale is built on the premise of a pure
additive effect of different anticholinergic loads and does not
consider possible synergistic or antagonistic effects of medica-
tions at the receptor level.
In relation to other findings.
With advancing age, the consumption of medications will rise
as well, and consequently the intake of anticholinergics will
rise [10]. Other studies estimate that up to 51% of the commu-
nity-dwelling population take medications with anticholinergic
properties [41], yet interpretation of this prevalence should be
performed with caution. Depending on the method used for
classifying anticholinergics, the prevalence of anticholinergic
use in just one population of older community-dwelling men
could range between 13 and 39% [42].
Our findings are in concordance with other studies, search-
ing for associations between patient characteristics and the use
of anticholinergics. The association of anticholinergic use with
female gender, age, depression, the number of medications,
multi-morbidity and with the number of medications have
been observed before [43–45]. In this study, the association
with cognitive impairment was absent [6,21], as older adults
without dementia were included in the Belfrail-med cohort.
Graph 1. Survival analysis of groups of MARANTE scale (no, low and high anticholinergic exposure) for mortality and hospitalization.
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Anticholinergics have been considered as potentially inap-
propriate [46,47] and are widely regarded as to be used with
caution in older persons. However, the definition of
medications with anticholinergic properties varies significantly,
leading to a multiplicity of lists and explicit criteria, making a
direct comparison difficult to perform. In addition, given dif-
ferent samples used, and different cut-offs for what high anti-
cholinergic exposure is [48], associations with mortality and
hospitalization remain inconclusive or even contradictory.
Previous publications did not find consistent associations of
anticholinergic exposure with mortality or hospitalization
[13,16,17,26–28,43,49]. Limiting the results to the oldest old
(aged 80 years and older), one longitudinal study reported sig-
nificant associations with mortality [27], while others did not
[13,16,26]. For hospitalization, in one publication, a signifi-
cant, yet limited association was found in the oldest old [28].
Our findings suggest an increase in mortality and first
unplanned hospitalization with high anticholinergic exposure.
Although associations were absent for a low anticholinergic
exposure, the risks were still increased for outcome of both.
The clinical relevance of a low anticholinergic exposure must
not be disregarded. A low anticholinergic exposure might
be associated with other clinical problems (e.g. more anti-
cholinergic side effects).
Implications for Practice.
Medication prescribers will need education and assistance to
appreciate the importance of these ‘invisible’ anticholinergic
medicines (and the patient contexts in which they are pre-
scribed) and to incorporate calculations of individual patient
anticholinergic exposure into their clinical decision-making.
This has the potential to reduce patients’ anticholinergic expo-
sure and adverse drug events.
Medications with anticholinergic properties are not always
known to prescribers [7], nor are anticholinergic side effects rec-
ognized. The array of tools and methods available, each using
Table 4.
Univariable analysis of the place of anticholinergic exposure and con-
founding variables in association with mortality and first hospitalization
Continuous Range
Mortality Hospitalization
HR (95% CI) HR (95% CI)
Anticholinergic exposure
Number of
anticholinergics
0–4 1.40 (1.02–1.93) 1.39 (1.17–1.67)
Potency score 0–5 1.33 (1.04–1,70) 1.32 (1.15–1.52)
Dosage score 0–6 1.26 (1.01–1.58) 1.29 (1.14–1.45)
MARANTE scale 0–7 1.22 (1.02–1.47) 1.25 (1.13–1.38)
Categorical
Taking
anticholinergics
(N = 160)
2.13 (1.19–3.82) 1.69 (1.23–2.33)
MARANTE scale (Cut-off)
No: 0 (N = 343) Ref Ref
Low: 0.5–1.5
(N = 81)
1.52 (0.68–3.39) 1.14 (0.73–1.79)
High: ≥2 (N = 79) 2.77 (1.43–5.38) 2.36 (1.63–3.42)
Confounding variables
Number of
medications
0–16 1.12 (1.02–1.22) 1.14 (1.08–1.20)
Age (years) 80–102 1.09 (1.01–1.16) 1.04 (0.998–1.08)
Categorical
Female gender 0.94 (0.52–1.70) 0.89 (0.65–1.22)
Low education
(≤8 years)
0.83 (0.45–1.55) 1.03 (0.73–1.45)
Living alone 1.15 (0.64–2.07) 1.06 (0.77–1.46)
Multi-morbidity1 1.36 (1.15–1.59) 1.25 (1.14–1.36)
Polypharmacy 1.87 (0.98–3.56) 1.69 (1.21–2.36)
1Multi-morbidity was expressed using the CIRS.
Table 5.
Multi-variable Cox regression analysis of mortality (8.9%) and hospitalization (31%) in association with the anticholinergic exposure in a cohort of
oldest old (n = 503).
Approach 1
Continuous Range
Mortality, HR (95% CI) Hospitalization, HR (95% CI)
Model 1 Model 2 Model 1 Model 2
Number of anticholinergics 0–4 1.18 (0.80–1.74) 1.14 (0.77–1.67) 1.14 (0.92–1.41) 1.12 (0.90–1.38)
Potency score 0–5 1.17 (0.86–1.58) 1.14 (0.84–1.55) 1.12 (0.95–1.33) 1.12 (0.94–1.32)
Dosage score 0–6 1.13 (0.86–1.47) 1.09 (0.83–1.42) 1.13 (0.98–1.31) 1.11 (0.96–1.28)
MARANTE 0–7 1.11 (0.89–1.39) 1.09 (0.87–1.36) 1.12 (0.99–1.26) 1.10 (0.98–1.25)
Approach 2
Categorical: Cut-offs n Model 1 Model 2 Model 1 Model 2
MARANTE
No: 0 343 Ref Ref Ref Ref
Low: 0.5–1.5 81 1.35 (0.59–3.08) 1.31 (0.57–3.02) 0.93 (0.59–1.49) 0.93 (0.58–1.47)
High: ≥2 79 2.26 (1.07–4.78) 2.20 (1.03–4.67) 1.75 (1.16–2.64) 1.71 (1.13–2.59)
Two approaches models were used. In the first one, associations of anticholinergic exposure with the continuous variable were analysed (e.g. the
number of medications and the continuous MARANTE score). In the second model, we performed categorical analysis to search for trends for a
higher risk of mortality or hospitalization with a higher anticholinergic exposure.
Two models were used, where model 1 was adjusted for the number of medications (0–16), and model 2 was additionally adjusted for the level of
multi-morbidity (0–9).
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different medications, can lead to confusion in knowing the true
anticholinergic properties of medications. The MARANTE scale
can aid medication prescribers to recognize those patients with
high anticholinergic exposure and to monitor these patients
more systematically for their experienced side effects.
Past and recent interest in anticholinergics in older adults,
understresses the importance of a consensus on a unified list
of medications with anticholinergic properties, with agree-
ments on their potency and dosages. We therefore invite other
researchers to an open discussion at https://secureramit.uge
nt.be/marante.
A computerized application of the MARANTE scale in
older adults can be used to implement particular explicit crite-
ria of inappropriate prescribing in automated systems of deci-
sion support and quality assurance, but it should not be used
as a substitute for the clinical assessment of the pharmacologi-
cal therapy of an individual patient.
Implications for research.
This cohort consisted of relatively healthy and active older
adults (aged 80 years and older). It would also be interesting
to examine the effects of a high anticholinergic exposure in
older adults, aged 65 years and older. Also the associations of
a higher anticholinergic exposure with outcomes are to be
studied in more frail patients in nursing homes, where there
are more patients with dementia, who are more susceptible to
the anticholinergic effects [1,5]. Older adults in nursing homes
have a higher medication intake, predominantly more psy-
chotropic medications and possibly a higher anticholinergic
exposure [50,51].
Finally, it is important to relate the anticholinergic expo-
sure to the anticholinergic burden, for example the direct
burden perceived by patients. Other studies reported associa-
tions of anticholinergic exposure with lower quality of life
[52], possibly due to a higher prevalence of common anti-
cholinergic adverse effects (sedation, hallucinations, dry
mouth or constipation). Therefore, in a following study, we
will investigate associations of anticholinergic exposure
(quantified by the MARANTE scale) with the anticholinergic
burden.
Conclusion
In a cohort of community-dwelling oldest old (aged 80 years
and over), a high prevalence of anticholinergic use was
observed, predominantly in high and very high dosages. The
novel MARANTE scale provided a robust estimation of the
anticholinergic exposure, but further validation is still needed.
Those with high anticholinergic exposure showed increased
risks of mortality and hospitalization.
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